echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > HALPRYZA, Xinda Bio's lyxid anti-injection fluid, was approved by NMPA for the treatment of malignant lymphoma.

    HALPRYZA, Xinda Bio's lyxid anti-injection fluid, was approved by NMPA for the treatment of malignant lymphoma.

    • Last Update: 2020-10-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Cynda Bio announced that its recombinant human/rat-embedded monoclonal antibody HALPRYZA (Lytoxi monoantigen injection) developed with Lilly has been officially approved by the State Drug Administration of China (NMPA) for the treatment of diffuse large B-cell lymphoma (DLBCL), filthy lymphoma (FL) and chronic lymphocytic leukemia (CLL).
    HALPRYZA is the fourth monoclonal antibody drug approved by Cinda Bio and the second NMPA approved monoclonal antibody drug developed by Cinda and Lilly after TYVYT (Sindelli monoantigen injection), BYVASDA (Beva monoantigen injection) and SULINNO (Adamo monoantigen injection).
    about malignant lymphoma Malignant Lymphoma is one of the most common blood malignancies in China, and the incidence of malignant lymphoma has been increasing in recent years.
    according to histopathology, lymphoma can be classified as Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), of which the NHL is the majority.
    more than 95% of B-cell non-Hodgkin's lymphoma cells express CD20.
    About HALPRYZA (Lytoxi monoantigen injection) HALPRYZA is a recombinant human/rat chiclonal antibody drug, lytoxic monoantigen binds to CD20 antigens on the surface of B lymphocytes, and mediates complement-dependent cytotoxicity (CDC) and antibody-dependent cytotoxicity (ADCC).
    picture source:
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.